Kedrion S.p.A.
Kedrion Biopharma is a global biopharmaceutical company focused on collection and fractionation of human plasma to manufacture and distribute plasma-derived therapies for rare and serious diseases. The group operates multiple production plants across several countries, a network of plasma collection centers, and provides services including contract manufacturing, technology transfer and biological safety testing. Kedrion reports regulatory approvals for its facilities and products and distributes therapies in over 100 countries.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Process for highly selective purification of two plasma proteins: von willebrand factor (vWF) and fibronectin (Fn)
US-9422361-B2
View DetailsTransferrin for use in the treatment and/or prophylaxis of autoimmune diseases
US-9138454-B2
View DetailsProcess for the industrial-scale purification of gamma globulins from human plasma for industrial applications
US-8933204-B2
View DetailsProcess for the preparation of a virus-inactivated FV concentrate starting from human plasma, scalable to industrial level
US-8822643-B2
View Details
Process for highly selective purification of two plasma proteins: von willebrand factor (vWF) and fibronectin (Fn)
US-9422361-B2
View DetailsTransferrin for use in the treatment and/or prophylaxis of autoimmune diseases
US-9138454-B2
View DetailsProcess for the industrial-scale purification of gamma globulins from human plasma for industrial applications
US-8933204-B2
View DetailsProcess for the preparation of a virus-inactivated FV concentrate starting from human plasma, scalable to industrial level
US-8822643-B2
View DetailsProducts
Plasma-derived immunoglobulins
Intravenous and subcutaneous human immunoglobulin therapies derived from pooled human plasma for treatment of immunodeficiencies and other indications.
Human albumin solutions
Pharmaceutical-grade human albumin solutions manufactured from plasma for clinical use.
Coagulation factors and related plasma proteins
Purified plasma-derived coagulation factors and complexes for bleeding disorders and related conditions.
Hyperimmune immunoglobulins and other specialty plasma products
Hyperimmune globulins and other plasma-protein derived specialty therapeutics for specific prophylactic or post-exposure indications.
Plasma-derived immunoglobulins
Intravenous and subcutaneous human immunoglobulin therapies derived from pooled human plasma for treatment of immunodeficiencies and other indications.
Human albumin solutions
Pharmaceutical-grade human albumin solutions manufactured from plasma for clinical use.
Coagulation factors and related plasma proteins
Purified plasma-derived coagulation factors and complexes for bleeding disorders and related conditions.
Hyperimmune immunoglobulins and other specialty plasma products
Hyperimmune globulins and other plasma-protein derived specialty therapeutics for specific prophylactic or post-exposure indications.
Services
Outsourced plasma fractionation and manufacturing services for external partners, including process development and production support.
Outsourced plasma fractionation and manufacturing services for external partners, including process development and production support.
Expertise Areas
- Plasma-derived therapeutics development
- Plasma collection and donor network management
- Plasma fractionation and protein purification
- Contract manufacturing and technology transfer
Key Technologies
- Plasma fractionation
- Plasma protein purification processes
- Virus inactivation and prion clearance methods
- Immunoglobulin production processes
News & Updates
Press release summarizing the company's financial results for 2025.
Press release announcing FDA approval and US availability of an intravenous immunoglobulin product.
Press release reporting EMA orphan drug designation for a plasma-derived therapy intended for a rare genetic iron‑metabolism disorder.
Press release summarizing the company's financial results for 2025.
Press release announcing FDA approval and US availability of an intravenous immunoglobulin product.
Press release reporting EMA orphan drug designation for a plasma-derived therapy intended for a rare genetic iron‑metabolism disorder.